In a recent study, researchers use single cell sequencing of intestinal tissue biopsies from diseased and healthy patients to create a cell atlas that lends novel insight into the cellular pathways that link implicated genes to UC pathophysiology.
Interview with Dr. Duane Wesemann, an Assistant Professor at Harvard Medical School, and a Principal investigator in the Division of Rheumatology, Immunology and Allergy at the Brigham and Women’s Hospital.
Fecal Microbiota Transplant (FMT) is gaining traction as a potentially effect treatment of the increasing number of diseases that have been linked to microbiome dysbiosis.
To look for associations between the gut microbiome composition and development of Type 2 Diabetes, CMIT collaborated with researchers at institutes and hospitals within Mexico to study a cohort that had not been been diagnosed with, or treated for T2D, avoiding the potential influences of medication and lifestyle changes on gut microbes.
The Center for Microbiome Informatics and Therapeutics was founded to accelerate the development of therapeutics to treat microbiome-associated disease, with a core focus on Inflammatory Bowel Disease (IBD).
In a recently published paper in Nature, Lloyd-Price (et.al) provide a comprehensive analysis of the longitudinal variation in the gut microbiome of patients with IBD.
CMIT is collaborating with Dr. Patricia Pringle and Dr. Raymond Chung from Massachusetts General Hospital (MGH) on a new study that is investigating the potential role of fecal microbiota transplantation (FMT) as a treatment for hepatic encephalopathy.